JP4684655B2 - ４−ヒドロキシタモキシフェンによる乳房密度低下 - Google Patents

４−ヒドロキシタモキシフェンによる乳房密度低下 Download PDF

Info

Publication number
JP4684655B2
JP4684655B2 JP2004560488A JP2004560488A JP4684655B2 JP 4684655 B2 JP4684655 B2 JP 4684655B2 JP 2004560488 A JP2004560488 A JP 2004560488A JP 2004560488 A JP2004560488 A JP 2004560488A JP 4684655 B2 JP4684655 B2 JP 4684655B2
Authority
JP
Japan
Prior art keywords
hydroxy tamoxifen
breast
tamoxifen
tissue
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004560488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514645A (ja
JP2006514645A5 (enExample
Inventor
ジェイ ブア、
Original Assignee
ラボラトワール ブザン アンテルナスィヨナル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトワール ブザン アンテルナスィヨナル filed Critical ラボラトワール ブザン アンテルナスィヨナル
Publication of JP2006514645A publication Critical patent/JP2006514645A/ja
Publication of JP2006514645A5 publication Critical patent/JP2006514645A5/ja
Application granted granted Critical
Publication of JP4684655B2 publication Critical patent/JP4684655B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2004560488A 2002-12-18 2003-12-15 ４−ヒドロキシタモキシフェンによる乳房密度低下 Expired - Lifetime JP4684655B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43395802P 2002-12-18 2002-12-18
PCT/EP2003/015030 WO2004054558A2 (en) 2002-12-18 2003-12-15 Reduction of breast density with 4-hydroxy tamoxifen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010279107A Division JP2011052020A (ja) 2002-12-18 2010-12-15 ４−ヒドロキシタモキシフェンによる乳房密度低下

Publications (3)

Publication Number Publication Date
JP2006514645A JP2006514645A (ja) 2006-05-11
JP2006514645A5 JP2006514645A5 (enExample) 2007-02-08
JP4684655B2 true JP4684655B2 (ja) 2011-05-18

Family

ID=32595254

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004560488A Expired - Lifetime JP4684655B2 (ja) 2002-12-18 2003-12-15 ４−ヒドロキシタモキシフェンによる乳房密度低下
JP2010279107A Pending JP2011052020A (ja) 2002-12-18 2010-12-15 ４−ヒドロキシタモキシフェンによる乳房密度低下

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010279107A Pending JP2011052020A (ja) 2002-12-18 2010-12-15 ４−ヒドロキシタモキシフェンによる乳房密度低下

Country Status (6)

Country Link
US (1) US7485623B2 (enExample)
EP (3) EP2050443B1 (enExample)
JP (2) JP4684655B2 (enExample)
AU (1) AU2003296757A1 (enExample)
DE (1) DE60327363D1 (enExample)
WO (1) WO2004054558A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053292A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
WO2004087123A1 (en) * 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
MXPA05007266A (es) * 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
ES2304610T3 (es) 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
MXPA06010914A (es) * 2004-03-22 2006-12-15 Besins Int Lab Tratamiento y prevencion de enfermedades de mama benigna con 4-hidroxi tamoxifen.
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
GEP20104889B (en) * 2004-10-14 2010-02-10 Laboratoires Besins Int 4-hydroxy tamoxifen gel formulations
GB0602739D0 (en) * 2006-02-10 2006-03-22 Ccbr As Breast tissue density measure
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
CN101861142A (zh) * 2007-11-22 2010-10-13 诺沃-诺迪斯克保健股份有限公司 含醛化合物对液体配制因子VII(a)多肽的稳定化
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP3143392B1 (en) * 2014-05-12 2023-02-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen metabolites by mass spectrometry
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
US12201591B2 (en) 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
WO2023026139A1 (en) * 2021-08-23 2023-03-02 Singh Divya Dhananjay Pharmaceutical composition comprising 4- hydroxytamoxifen for the treatment of mastalgia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
TW218849B (enExample) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
JPH0679002A (ja) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc 経皮投与用パッチシステム
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
DE4434165A1 (de) * 1994-09-24 1996-03-28 Cassella Ag Haarfärbemittel
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
WO2004087123A1 (en) * 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
ES2304610T3 (es) 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
WO2004054558A3 (en) 2004-10-28
JP2011052020A (ja) 2011-03-17
US20040138314A1 (en) 2004-07-15
EP1952809A3 (en) 2012-06-20
US7485623B2 (en) 2009-02-03
EP2050443A1 (en) 2009-04-22
WO2004054558A2 (en) 2004-07-01
DE60327363D1 (de) 2009-06-04
JP2006514645A (ja) 2006-05-11
EP1952809B1 (en) 2017-08-02
EP1572171B1 (en) 2009-04-22
EP1572171A2 (en) 2005-09-14
AU2003296757A1 (en) 2004-07-09
EP1952809A2 (en) 2008-08-06
EP2050443B1 (en) 2017-05-24
AU2003296757A8 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
JP4684655B2 (ja) ４−ヒドロキシタモキシフェンによる乳房密度低下
JP2006514967A (ja) ４−ヒドロキシタモキシフェンによる乳癌の予防および治療
JP4938237B2 (ja) ４−ヒドロキシタモキシフェンによる乳房痛の治療
JP4682129B2 (ja) ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
JP5489407B2 (ja) ４−ヒドロキシタモキシフェンの化学的に安定な組成物
EP1579856A1 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
JP5072588B2 (ja) ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防
JP2007529420A (ja) 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用
HK1130435A (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1077512B (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1077512A1 (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1130435B (en) Reduction of breast density with 4-hydroxy tamoxifen
MXPA05013435A (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110209

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4684655

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term